Sunday - November 15, 2026
Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO(tm) (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer
November 05, 2026
NEW BRUNSWICK, New Jersey, Nov. 5 [Category: BizHealth & Beauty] -- Johnson and Johnson posted the following news release:

* * *

Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO(tm) (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer

*

New Brunswick, N.J. (November 5, 2026) - Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administr . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products